Monitoring aptamer-protein interactions using Tunable Resistive Pulse Sensing by Emily R. Billinge (7162754) et al.
1 
 
Monitoring Aptamer-Protein Interactions using Tunable Resistive Pulse 
Sensing. 
 
 Emily R. Billinge1, Murray Broom2, Mark Platt1*  
 
1 Department of Chemistry, Centre for Analytical Science,  Loughborough University, 
Loughborough, LE11 3TU, United Kingdom. 
2 Izon Science Ltd., PO Box 39168, Burnside, Christchurch 8053, New Zealand. contact : 
murray@izon.com 
 
*Correspondence should be sent to m.platt@lboro.ac.uk  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Abstract -  
Aptamers are short single-stranded pieces of DNA or RNA capable of binding to analytes 
with specificity and high affinity. Due to their comparable selectivity, stability and cost, over 
the last two decades aptamers have started to challenge antibodies in their use on many 
technology platforms. The binding event often leads to changes in the aptamer’s secondary 
and tertiary structure; monitoring such changes has led to the creation of many new analytical 
sensors. Here we demonstrate the use of a tunable resistive pulse sensing (TRPS) technology 
to monitor the interaction between several DNA aptamers and their target – thrombin. We 
immobilised the aptamers onto the surface of superparamagnetic beads, prior to their 
incubation with the thrombin protein. The protein binding to the aptamer caused a 
conformational change resulting in the shielding of the polyanion backbone; this was 
monitored by a change in the translocation time and pulse frequency of the particles 
traversing the pore. This signal was sensitive enough to allow the tagless detection of 
thrombin down to nanomolar levels. We further demonstrate the power of TRPS by 
performing real time detection and characterisation of the aptamer-target interaction and 
measuring the association rates of the thrombin protein to the aptamer sequences.  
 
Key words – Thrombin, Aptamer, Resistive pulse sensing, superparamagnetic beads, 
association rate, biosensor. 
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Introduction -  
In recent years, developments in the field of diagnostics and biosensor technologies 
have been aided by the use of nanomaterials1-5. Synthesis and fabrication methods for 
nanoparticles in solution have evolved to the extent that particle size, shape, and composition 
can be easily modified. Technology platforms have also become more robust and 
reproducible to the extent that assays based upon nanomaterials offer significant advantages 
over conventional diagnostic systems with regard to assay sensitivity, selectivity, and 
practicality6-13. Following the advancement of material synthesis, a range of new 
characterisation technologies capable of monitoring and measuring the size, surface 
chemistry, shape, optical, magnetic and even electrochemical properties have emerged14-20. 
Furthermore, with current synthesis strategies, materials can all be modified with a range of 
surface chemistries, patterning, and even functionalised with biomolecules21.  
Within the fields of biosensors and diagnostics there is an increasing drive to reduce the 
time taken to yield a result from the point of sampling. With a desire to move towards point 
of care (POC) diagnostics, and facilitated by the miniaturisation of components, technologies 
previously used solely for particle characterisation are now being incorporated into sensor 
and diagnostic technology platforms. Light scattering19, fluorescence9,12,22, magneto-
resistance and flow cytometry23,24 are now routinely used for particle characterisation as well 
as the detection of cells, proteins, and genomic and metabolomic analytes. 
Each technology carries its own advantages and limitations regarding sensitivity, the 
ability to multiplex, biocompatibility and assay time. Current bioassays, such as those done 
by microscopy, are often inaccessible in resource-poor areas due to their running and 
maintenance costs, and need for skilled operators25. In recent years, nanopore systems 
utilising Coulter technology have seen resurgence, allowing the characterisation of colloid 
and nanoparticle based systems26. Known collectively as resistive pulse sensing (RPS), they 
offer an attractive technology format because the measurements provide information on 
individual particles within their natural environment14,27-30. RPS has been used to study 
numerous types of particles in different contexts with impressive resolution, including single 
molecule biophysics, protein sensing, biological detection27,28,30 and synthetic nanoparticle 
characterisation31,32.  A recent adaptation to RPS termed tunable resistive pulse sensing 
(TRPS)17,30 uses a conical tunable elastomeric pore allowing  further versatility as the pore 
can be stretched in real time to suit the sample15. TRPS has been validated to accurately 
determine the concentration31, size32 and surface charge of dispersed inorganic particles. The 
technique is a relatively inexpensive off the shelf instrument. The only consumable is the 
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tunable pore, thus eliminating the need for a carrier gas, fluidics, or optics. Previously, TRPS 
has been utilised  to monitor the aggregation of a special class of nanomaterial, termed 
nanorods, in the presence of analytes16, and the aggregation of gold nanoparticles in the 
presence or absence of DNA to detect single nucleotide polymorphisms33.  
The interaction between an analyte and the particle is key to providing a selective and 
sensitive assay format. Where previously antibodies have been the capture probe of choice, 
aptamer technologies are gaining interest34-37. Aptamers are powerful reagents that bind target 
ligands with affinities comparable to antibodies.  Aptamers are conventionally generated 
through the process known as SELEX38,39 (systematic evolution of ligands by exponential 
enrichment), where strong binding sequences are evolved/enriched from extensive libraries, 
or by CLADE40-43 (closed loop aptameric directed evolution) which produces the aptamers 
'on-chip'. During the CLADE cycle the selection, modification and evolution of the DNA 
sequences are carried out in silico using a genetic algorithm (GA) to optimise the binding 
strength42,43.  
The modification of particle surfaces with aptamers should be a process well suited to 
RPS technologies. Information on size and surface charge can be measured simultaneously 
by analysing the pulse observed as a particle traverses the pore, displayed schematically in 
figure 1A.  
 
Figure 1: A (i) Schematic representation of a particle traversing the pore opening. (ii); Schematic 
representation of a pulse that occurs as the particle traverses the opening. The blockade magnitude 
(Δip), is used to determine individual particle size; full width half maximum (FWHM) gives an 
indication of the time taken to traverse the pore. B Schematic of the experimental process, (i-ii) a 
bead functionalised with streptavidin is incubated with biotin tagged DNA, (iii) After removing any 
unbound DNA from the solution, the target protein is added to the sample. 
A stable ionic current is established upon the application of an applied potential, and 
as the particles enter the pore orifice there is a measurable increase in resistance; the 
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occlusion of ions results in a transient decrease in current. The conical pore gives rise to an 
asymmetric current pulse as resistance diminishes toward the base of the pore44. 
For a conical pore, the change in resistance, ∆R, across the length of the pore, L, is 
given by equation 145, 
 
Δ𝑅 =  𝜌 ∫ 𝑑𝑑
𝐴(𝑑)𝐿0 − 𝑅          (1)  
 
where ρ is the resistivity of the electrolyte filling the pore, A(z) is the cross sectional area 
perpendicular to the pore axis z, and R is the pore resistance when no blockage is present 
given by equation 245, 
 
𝑅 = 4𝐿𝐿
𝜋𝐷𝐿𝐷𝑠
           (2) 
 
where DL and Ds are the large and small pore diameters. The size of any biological or 
inorganic particle that traverses the pore, can be determined by measuring the change in 
resistance. Heins et al’s work used this relationship to monitor and model the translocation 
events of small molecules45. Kozal et al recently derived a similar relationship between the 
change in resistance within a conical pore using an elastic pore sensor, which closely predicts 
the ∆R with nanoparticles traversing the pore46. Conical nanopores are of particular interest 
due to the localization of a narrow sensing zone at the small pore orifice, and modeling the 
pulse shape and magnitude within such pores is nontrivial 44,47-49.  The frequency of the 
pulses J, can be related to the concentration of the analyte, Cs, as well as the velocity of the 
traversing particle, vp. 
The velocity term is the sum of the fluidic, vF electrophoretic, vE, and electroosmotic, 
vO, velocities i.e. vp = vF + vE + vO. Here we ignore the contribution from diffusion due to the 
magnitude of other forces46 and end effects are not taken into account in the analysis44. vp can 
be written as50; 
𝑣𝑝 = 𝑄
𝜋�
𝐷𝑆
2
�
2  + 𝜖𝜁𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝜂 𝐸 − 𝜀𝜁𝑝𝑝𝑝𝑝𝜂 𝐸                (3) 
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Where 𝑄 =  3𝜋𝐷𝑠3Δ𝑃
128𝜂�
𝐿
𝐷𝐿−𝐷𝑆
�
         (3a) 
ε and η is the permittivity and kinematic viscosity, ∆P is the pressure across the pore, ζpore 
and ζparticle is the zeta potential of the channel surface and particle respectively, E is the 
electric field. The pulse frequency, J, is then related to both the velocity and the particle 
concentration Cs, via the equation44,51; J = Cs×𝑣𝑝. For the system used in this study it has 
been demonstrated that the forces of electrophoresis, electro-osmosis and pressure are usually 
dominant15,17,31,32,52. Therefore, if the pressure, ionic strength and composition of the buffer 
do not change during the experiments and the pore surface charge remains constant, any 
observed differences can be inferred to be due to the electrophoretic mobility. Particles that 
have been modified with strands of DNA should result in a change in particle frequency and 
duration over unmodified beads as the electrophoretic mobility is altered.  In addition, the 
RPS technology should be able to monitor the interaction between the DNA and any analyte 
that binds to it, as such interactions should result in a conformational change and shielding of 
the DNA charge. 
 Here we demonstrate the use of TRPS technology to observe the interaction between 
aptamer modified superparamagnetic particles with their target protein, thrombin. Thrombin 
was chosen as it is one of the first and most widely studied aptamers, and its binding 
mechanism is well characterised and understood38,53,54. Whilst thrombin itself is an important 
biomarker and plays a role in the coagulation cascade and cardiovascular disorders55, there 
are many methods and technology platforms for its quantification, and it is often used to 
validate emerging aptamer technologies and hence its use here56. In the presence of thrombin, 
aptamer sequences containing a “GGNNGGNGNGGNNGG” (where N represents T or A) 
motif undergo a conformational change to form a G-quadruplex structure57. As it possesses 
such a well-studied structure, it also allows us to use modified thrombin aptamer sequences 
where we deliberately control and modify the binding shape to study the effects upon the 
signal in the TRPS43,53.  
The immobilisation of the DNA onto the particle surface is confirmed by changes in 
the observed particle count rate and decrease in translocation times. These results confirm the 
change in surface charge from a relatively neutral to highly negative surface. The incubation 
of the thrombin target with the beads causes a shielding effect, where the thrombin protein 
masks the negative charge and the particle count rate and translocation times change.  This 
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interaction forms the basis of a real time sensor with limits of detection down to nanomolar 
levels of thrombin with assay times of 3 minutes. The sensitivity of the TRPS allows us to 
monitor the binding kinetics of three different thrombin aptamers. Using this technique we 
are able to calculate a dissociation constant for the particle-thrombin reaction on the order of 
39 × 10-9 M. 
 
Methods -  
Chemicals and reagents 
The following chemicals were sourced from Sigma Aldrich, United Kingdom, without any 
further purification unless otherwise stated: phosphate buffered saline (PBS - P4417), Tween 
20 (P1379), Bovine Serum Albumin (BSA - A2153), and thrombin (T7513). DNA sequences 
were purchased as lyophilised powders with HPLC purification from Entelchon (Germany) : 
5’GGT TGG TGT GGT TGG TTT TTT TTT T-Biotin-3’ (Thrombin-15) and 5’TGG GAG 
TAG GTT GGT GTG GTT GGG GCT CCC CTT TTT-Biotin-3’ (Thrombin-MArray). The 
sequences 5’GGT TGG TTT ATT TTA CTA GTG GCC AGG-Biotin-3’ (ThrombinEvol) 
and a random biotin-tagged 10mer were purchased as lyophilised powders with HPLC 
purification from Sigma-Aldrich (UK).  These were made up to a stock concentration of 
100pmol/μL with deionised water. 
Particles  
Streptavidin modified superparamagnetic particles of 128nm diameter were purchased from 
Ademtech (France). Carboxyl beads of known concentration and diameter (203 nm) were 
sourced from Izon Science (Christchurch, New Zealand) and used as a calibrant at a 
concentration of (4×109 particles/mL). Water purified to a resistivity of 18.2 MΩ cm 
(Maxima) was used to make all solutions unless otherwise specified. In all experiments 
1×PBST (0.05% Tween) was used as the buffer. 
Binding assays 
Immobilisation of DNA onto the beads 
128nm streptavidin coated beads were diluted to a concentration of approximately 3 × 109 
particles/mL; this stock was vortexed and sonicated to ensure monodispersity. To 40μL of 
beads a further 10μL of varied ratios of PBST and aptamer dilutions was added to provide a 
range of final concentrations from 0.1nM up to 10 000nM of DNA. These were vortexed and 
placed on a rotary wheel for 30 minutes at room temperature prior to analysis. 
Thrombin Binding Assay: Bead preparation: 
8 
 
 Step 1 – attachment of aptamer onto the beads 
128nm beads were diluted in PBST to a concentration of approximately 3 × 109  
particles/mL. A ten-fold excess of biotinylated DNA (according to the binding capacity of the 
supplier) was added to the beads and incubated at room temperature for 30 minutes. In 
control experiments the same concentration of a random 10mer was added and the same 
procedure followed. 
Step 2 – removal of excess DNA 
The sample was centrifuged for 2 minutes at 10 000 rpm and immediately placed in a 
MagRack (Life Sciences). After 5 minutes the beads had formed a visible cluster in the 
sample vial adjacent to the magnet and the solution was carefully removed and replaced with 
an equal volume of PBST. This wash stage was performed twice.  
Step 3a – Thrombin concentration investigation 
A variety of concentrations of thrombin protein was added to the beads which were then 
incubated on a rotary wheel for 30 minutes before analysis, these ranged from a final 
concentration of 0.1nM – 10000nM. In these experiments the concentration of the beads was 
kept constant. 
Step 3b – real time binding experiments  
36μL of washed bead-aptamer sample, described in step 2, was pipetted into the upper fluid 
cell of the TRPS instrument, this dispersion was recorded for 60 s at which time the software 
was paused and 4μL of the required test solution was added into the solution. Recording was 
immediately resumed. Data was then captured for a minimum of 60 seconds and included a a 
minimum of 50 data points. The addition of the 4 µl of solution required the pipette tip to be 
placed into the liquid, the 4 µl was then added and the tip removed. Other than the convection 
caused by the removal of the tip no additional stirring was induced.  
 
Tunable Resistive Pulse Sensing (TRPS) 
Measurements were made using the qNano system obtained from Izon Science 
(Christchurch) incorporating the fluid cell, stretching apparatus, data recording and analysis 
software (v.2.2).  The pores used were designated ‘NP200’ by the manufacturer, and are 
described as most suitable for detecting particles in the range 100 – 300 nm.  The 
macroscopic stretch applied to the membrane is given in each figure legend.  An appropriate 
voltage (circa ~ 0.36V) was selected for all experiments to enable the detection of the peaks 
above the level of noise (< 10 pA). This was judged to be adequate when the peak magnitude 
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was greater than 0.12 nA. The pore stretch and applied voltage was the same for similar sets 
of experiments to allow us to compare data. Typically a bandwidth filter of 1 kHz was 
applied during measurements, and modal values from data histograms are used in all plots. In 
all experiments 80μL of electrolyte buffer was placed in the lower fluid cell. The volume in 
the upper fluid cell was typically 40μL unless experiments were being performed where a 
protein solution was added into the cell after 60 seconds. In this case the initial volume was 
36µl in the upper fluid cell and after 60 seconds 4µl of the solution was added giving a total 
volume of 40µl; after recording, this solution was withdrawn and the fluid cell and pore 
washed by repeatedly replacing PBST in the upper fluid cell until no particles were apparent 
on the signal trace. To generate error bars in all figures the mean and standard deviation of 
repeat experiments was used. 
 
Results and discussion -  
Binding of biotinylated DNA to the Streptavidin beads 
The first experiment modified the streptavidin coated beads with the biotinylated-Thrombin-
15, displayed schematically in figure 1B. A tenfold excess of DNA over the known binding 
capacity (final concentration of 171 nM) was added to ensure all the free binding sites were 
occupied. The beads were incubated at room temp for 30 minutes, before placing the sample 
into the TRPS instrument. During each experiment, the applied voltage always had a positive 
bias applied to the electrode underneath the membrane i.e. on the opposite to where the 
sample was placed, this orientation makes it easier to observe negatively charged beads3. We 
noted two distinct changes in the signal upon the binding of Thrombin-15 aptamer to the 
beads. The first was an increase in particle count rate from circa 100 to 400 beads per minute, 
and the second was a decrease in the FWHM values, from 1.2 ms to 0.3 ms, for the 
streptavidin and DNA coated beads respectively, and these trends were expected. In the setup 
used here the sample is placed into an upper fluid cell, and whilst the peak duration can be 
governed by pressure-driven flow in the present setup, the increase in electrophoretic 
mobility can clearly be observed. To demonstrate that this effect was dependent upon the 
quantity of DNA on the beads surface, the concentration of DNA was varied and the results 
are shown in, figure 2.  
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Figure 2:  Scatter plot displaying average rate (a) mode FWHM (b) against concentration of Thrombin-15 using 
a concentration of beads of 3 × 109 particles/mL.  A “NP200” pore with a membrane stretch of 44.50mm, 
voltage of 0.4V, and 40µl of sample in the upper fluid cell was used. Each data point represents the average 
value from four experiments and error bars represent 1 standard deviation from the mean.  
As the concentration of DNA increases, as did the coverage of DNA on the beads surface, the 
FWHM and particle rate decrease and increase respectively until a consistent value is 
obtained of around ~ 400 particles/min and 0.28 ms. In these experiments we failed to 
observe any increase in ∆ip, figure-S1, upon the binding of the DNA. This is most likely 
attributed to the low sensitivity of the pore system under the current stretch and voltage 
conditions used here to resolve these small changes in size. We repeated this experiment with 
a random biotinylated 10-mer, results shown in figure-S2. Whilst similar trends were 
observed we noted that the absolute change in values for both the particle rate and FWHM 
were smaller (100 to 250 beads per minute and 0.9 ms to 0.5 ms, respectively); this is not 
unexpected as the shorter sequence would produce a smaller charge density on the beads 
surface, therefore having a less profound effect on translocation events.   
 
Incubation of aptamer modified beads with thrombin protein –  
Having modified the streptavidin beads with the Thrombin-15 aptamer, we removed any 
unbound aptamer from solution by magnetically extracting the beads and suspending them in 
fresh buffer. The aptamer modified beads were then incubated with the thrombin protein for 
30 minutes, before 40 µl of sample was analysed in the TRPS. A range of concentrations of 
thrombin were used; figure 3A and 3B display plots of particle rate and FWHM values, 
respectively, for the Thrombin-15 (line a, solid red). As we increase the concentration of the 
protein the particle rate and FWHM values decrease and increase respectively. We attribute 
this to the protein binding to the aptamer and shielding some of the negative charge, shown 
schematically in figure 3Ci. At the higher concentrations of thrombin >10nM, further binding 
11 
 
of the thrombin protein cannot be observed using the particles rate as it remains relatively 
constant. However, the FWHM for thrombin 15, as displayed in figure 3B, does continue to 
rise. We have calculated that at concentrations of thrombin over 15nM, there are circa 2 
aptamers for every thrombin molecule, leading us to conclude that steric hindrance, rather 
than binding site saturation, is responsible for this. Plotted in figure-S3 is the relative size of 
the blockade events versus thrombin concentration, whilst thrombin may contain two 
epitopes, unlike previous studies here we do not observe any aggregation of the magnetic 
beads58,59. As a control we carried out the same experiment using a BSA protein, displayed in 
figure 3 (red dashed line – curve c). The particle count rate and FWHM remain constant 
across the entire concentration range of BSA, illustrating that the aptamer is specific to the 
thrombin target. This is an expected result given the depth of work using the sequence, but 
also verifies that the observed trends are unrelated to nonspecific interaction between the 
protein and DNA or surface of the beads. 
 
Figure 3: A Scatter plot displaying the effect of increasing concentrations of thrombin or BSA on rate and 
FWHM (inset) a  = Thrombin-15, b  = ThrombinMArray, c  = BSA control. A “NP200” pore with a membrane 
stretch of 44.50mm, voltage of 0.36V, and 40µl of sample in the upper fluid cell was used.  Each data point 
represents the average value from four experiments and error bars represent 1 standard deviation from the 
mean. B Schematic of the thrombin protein binding to the three different aptamer sequences.  
We also tested a second thrombin aptamer sequence, termed Thrombin-MArray, 
plotted in figure 3 (black – curve b). This sequence was previously optimised from one of the 
12 
 
original SELEX aptamers on a DNA microarray surface using a genetic algorithm53. The 
sequence contains the standard G-quadruplex, but also has complimentary strands of DNA 
flanking the quadruplex structure, forming a structure stabilising duplex. The measured 
affinity using SPR analysis for the Thrombin-MArray aptamer was comparable to the original 
Thrombin-1553. We chose this sequence as a comparison because research has shown that in 
some cases modifications of the original 15mer can in fact enhance the binding on 
surfaces53,60, leading to a greater sensitivity.  
The difference in the mechanism for binding thrombin between the two aptamers lies 
in the existence of the complimentary region in the Thrombin-MArray aptamer. In order to 
form a stable structure the sequences must fold in half, stabilised by the binding of the 
complementary regions, shown schematically in figure 3Cii. A plot of particle rate and 
FWHM versus thrombin concentration is shown in figure 3B (c – black line). Whilst we 
observe similar trends to those with the original 15mer, i.e. the particle rate drops at higher 
concentrations of thrombin, we noted that at lower concentrations of protein target very little 
deviation in the particle rate and FWHM was recorded. In addition, the total change in 
FWHM across the concentration range was much smaller, 0.29 to 0.34 ms.  
Again a control experiment using BSA protein was performed for this aptamer and 
the data are shown in figure-S4. There are two observations here worth discussing, the 
decrease in sensitivity, i.e. no observed a change in particle rate of FWHM at concentrations 
lower than 10 nM, and the small change in FWHM across the full range of thrombin 
concentrations for the Thrombin-MArray sequence.  
Both aptamer sequences have been previously characterised using standard surface 
plasmon resonance methods, and yielded similar, KD values. Upon scrutiny the reason for the 
deviations in behaviour may be attributed to the mechanism of binding. The binding of the 
protein to the Thrombin-MArray aptamer, shown in figure 3Bii, requires the DNA to fold 
back and form complementary base pairs near the particle surface, which stabilises the 
structure and allows the free lysine residue on the protein to bind to the G-quadruplex. In this 
orientation the thrombin protein is held close to the surface of the bead and neighbouring 
aptamer strands that are unbound extend out into solution. At low protein coverage, the 
dominant effect on the particle rate and FWHM is the protrusion of the phosphate backbone 
from the DNA past the protein, and as the coverage of thrombin on the surface increases and 
more aptamer strands are masked, the particle rate decreases.  
In both sets of experiments, it is unlikely that the number of bound proteins on the 
surface equals the total number of aptamers due to steric hindrance. The duration of 
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translocation, which can be inferred by FWHM, of the Thrombin-MArray beads at 
concentrations of thrombin  >10 nM remains lower than the Thrombin-15 indicating a higher 
negatively charged surface still exists, this we propose is due to the longer sequence and 
protrusion of the DNA past the bound protein. Because the change in particle rate was always 
easier to observe and more reproducible than the FWHM, we only show and use the rate data 
here after. 
Measuring the association rate –  
The above measurements were recorded after a 30 minute incubation period between the 
beads and target protein; this should be a sufficient time for the binding between the protein 
and aptamer to have occurred. Calculations based upon Smoluchowski theory61,62 suggest that 
the reaction should proceed quickly under the conditions and concentrations used here and 
binding between the protein and aptamer should occur within seconds. To ascertain if we 
could observe the binding to the beads in real time we placed 36 µl Thrombin -15 modified 
beads into the upper fluid cell; we collected data for 60 s to obtain a base particle rate, the 
data collection was paused whilst the thrombin protein was added to the upper fluid cell, 
before continuing data collection. The change in particle rate as a function of time, for four 
experiments repeated under the same thrombin concentration are displayed in figure 4A. To 
demonstrate that the addition of extra solution itself does not cause a significant change in 
particle count rate, the same volume of PBST without Thrombin was added into the upper 
fluid cell, data from repeat experiments shown in figure-S5 and table-S1. Typically the 
addition of the extra 4 µl of solution to the upper fluid cell caused a small deviation in the 
gradients of the line, on average the gradient of the line changed by around -4% upon the 
addition of the solution indicating a decrease in particle count rate. The particle rate was 
calculated at each data point using the equation-S1.  
 
14 
 
 
Figure 4: A, Replica experiments of real time particle rate measurements for Thrombin-15 modified beads. At t 
= 0 36µl of sample was present in the upper fluid cell, at t = 60s 4µL of Thrombin solution was added giving a 
final concentration of 15 nM. B, One set of experiment demonstrating the change in rate with respect to the 
concentration of thrombin. At t = 60s 4µL of Thrombin solution was added giving a final concentration of 
thrombin (navy blue) = 1.5 nM, b (red) = 3 nM, c (green) = 15 nM, d (blue) = 77 nM, e (purple) = 154 nM. C, Plot 
of rate of change in particle count, ln(R/R0), versus time, for the experiment shown in part B. t = 0 indicates the 
point at which thrombin was added to the particle solution. D, Plot of Kobs versus concentration of thrombin. 
The values represent the mean from four experiments. The data was obtained using a “NP200” pore with a 
membrane stretch of 44.50mm, an applied voltage of 0.4V. 
After the addition of the protein into the fluid cell we observed a decrease in particle count 
until a continuous value is obtained after approximately 120 s. The observed change in 
particle count is attributed to the same effect described above: the binding of the protein to 
the surface and the masking of the negative DNA backbone. As presented in figure 4A, the 
observed effects were reproducible over several measurements. Figure 4B illustrates the 
change in particle rate as a function of thrombin concentration, as the concentration of protein 
increases, the magnitude of the change and the speed of the change also increases. Plot e 
appears to deviate and change its rate prior to the additions of the protein. Upon inspection of 
the trace it appears that a blockage i.e. a period of time where no particles traversed the pore, 
occurred at 34 s, which lasted approx. 4 s, after this time the rate returned to a steady value. 
We show only one of triplicate measurements in figure 4b; figure-S6 shows the repeat 
measurements with the blockage highlighted. We also show the analysis of the particle rate 
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before and after the blockage in figure-S6c. In calculating the rates of reactions below we 
used the average value from all three measurements.    
As the thrombin protein is in excess of the beads concentration by several orders of 
magnitude, we assumed a first order reaction where a plot of the rate of change, ln(R/R0), 
versus time should yield a straight line with gradient of kobs. Here, R is used to represent 
instantaneous rate in a first-order rate equation. R was calculated by dividing equation-S1 by 
60, and R0 is average rate of particles per second, recorded in the 60 seconds prior to the 
injection of the protein and Kobs = ka[Thrombin]+kd. Thus a plot of Kobs versus concentration 
of thrombin should yield a straight line with the gradient of ka and an intercept of kd. Figure 
4C shows the rate of change versus time for five different thrombin concentrations, figure-S7 
illustrates the same analysis applied to the data given in figure 4A to allow a comparison of 
the reproducibility of the procedure. In the calculations a minimum of 60 s was collected after 
the injection of the protein to calculate the reaction rates.   
The gradients from each experiment are plotted as a function of concentration in 
figure 4D and from the regression line ka is calculated to be 7.42 × 104 M-1s-1, kd 2.9 × 10-3 s-1 
and gives a KD 39.1 nM, which is comparable to measurements reported in the literature of 6 
nM63, 20 nM59, 200 nM64, 102.6 nM65, and 75-100 nM66. We performed the same set of 
experiments for the Thrombin-MArray aptamer and obtained a ka of 4.03 × 104 M-1s-1, kd 
3.40 × 10-3 s-1 and KD 84.3 nM. This compares favourably to the value obtained by the 
authors using surface plasmon resonance techniques, SPR,  of 28 nM53. We noted again that 
when a low (<10nM) concentration of thrombin was used we failed to see a change in signal 
for the Thrombin-MArray aptamer. Figure 5A, curve a, illustrates the particle rate for the 
Thrombin-MArray, and curve c, the Thrombin-15, after the injection of the thrombin protein 
at t = 60 s, we fail to see any change in the rate for the Thrombin-MArray aptamer. This 
observation agrees with the data displayed in figure 3. 
We hypothesised that the difference in the observations for the two aptamers, which 
have similar ka and kd values from traditional SPR methods, is due to mechanistic effects, i.e. 
the protein is buried within a negative DNA layer, or the hindrance of the protein binding to 
the Thrombin-MArray aptamer on a beads surface rotating at ~ 400 s-1. As we increase the 
concentration of the protein in figure 5B – D from 15nM to 154 nM, we observe the rate of 
change for the Thrombin-MArray starts to increase and eventually matches that of the 
Thrombin-15.  Three control experiments are shown in figure S-9, in curve 1 BSA protein is 
added to the cell containing Thrombin-15 modified beads, curve 2 thrombin is added to 
carboxyl coated polystyrene beads, and curve 3, thrombin is added to a superparamagnetic 
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bead modified with a random 10mer. In each experiment no deviation or change in particle 
rate after the additional of the protein was observed.  
 
 
Figure 5: Real time particle rate measurements taken for three aptamers, curves are labelled a, b and c, 
representing data from Thrombin-MArray, ThromEvol and Thrombin-15 respectively. At t = 0 36µl of sample 
was present in the upper fluid cell.  A, 4µl of thrombin solution added at t = 60 s giving a concentration of 3 
nM. B, 4µl of thrombin solution added at t = 60 s giving a concentration of 15 nM. C, 4µl of thrombin solution 
added at t = 60 s giving a concentration of 45nM. D, 4µl of thrombin solution added at t = 60 s giving a 
concentration of 154 nM. The data was obtained using a “NP200” pore with a membrane stretch of 44.50mm, 
an applied voltage of 0.4V. Control experiments are represented in figure S-9. 
 
We tested a third aptamer, termed ThrombinEvol, which was raised via the CLADE 
technique43. This sequences does not contain the typical G-quadruplex motif but still 
possesses a reported ka of 8.7 × 104 M-1s-1, kd 2.04 × 10-3 s-1 and KD 23.45 nM43 when 
measured with SPR technologies. Importantly, this aptamer binds to the protein via the base 
pairs at the end of the sequences shown in figure 3Biii. This binding mechanism was hoped 
to lead to an improved sensitivity as unlike the Thrombin-MArray sequence the protein sits 
on top of the aptamer strands. The real time particle rate measurements for the sequences are 
presented in figure 5A – D (curves b). The ThrombinEvol sequence has an improved 
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response at the lower protein concentrations and consistently performs better than the 
Thrombin-MArray, figure-S8 shows one set of data illustrating the change of rate across the 
full range of concentrations. The measured reaction rates based upon triplicate measurements 
for the Evol aptamer were ka of 5.78 × 104 M-1s-1, kd 4.80 × 10-3 s-1, and KD 83.1 nM, see 
figure-S10 for the plot of Kobs versus concentration. Whilst this suggests the shielding of the 
charge via the protein is key in observing a change in particle rate, the clearest response 
across the full range of the protein concentrations was the original Thrombin-15 aptamer. 
These results suggest that whilst shielding the charge on the DNA is an essential part of the 
signal, to obtain a strong change in particle rate a conformational change must also take 
place.  
 
Conclusions -  
Here we present the use of TRPS to monitor the changes in surface functionality on 
superparamagentic beads. We utilise this signal to study the interaction of DNA aptamers 
with their target protein. The changes in signal, namely particle rate and FWHM, are 
sensitive enough to monitor the immobilisation of DNA on to the beads surface, and then the 
binding of the protein to the aptamers. Our results demonstrate that TRPS is now one of 
many technologies capable of monitoring the interaction between aptamers and their target 
protein. We have demonstrated that TRPS allows for real time monitoring of the protein-
aptamer interaction allowing the reaction rates to be calculated. This offers a new technique 
for monitoring the association rates of analytes directly on the beads surface without the need 
for identification labels such as fluorescence or utilising standard SPR technologies. The 
current method does have a limited working range, as at higher concentrations of target a 
reduced particle count rate makes obtaining a sufficient particle count difficult, evidence of 
this is in the increased size of the error bars at higher concentrations in figure 4D and S10. 
Work is underway in the laboratories to expand the dynamic range by varying the bead size 
and binding capacity of the surfaces. 
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